期刊
ANNALS OF ONCOLOGY
卷 28, 期 11, 页码 2806-2812出版社
OXFORD UNIV PRESS
DOI: 10.1093/annonc/mdx496
关键词
follicular lymphoma; lenalidomide; rituximab
类别
资金
- National Cancer Institute of the National Institutes of Health [U10CA180821, U10CA180882, U10CA007968, U10CA077597, U10CA180833, U10CA180850, U10CA180838]
- Celgene
- Dana-Farber/Partners CancerCare LAPS, Boston, MA [5U10CA180867]
- Delaware/Christiana Care NCI Community Oncology Research Program, Newark, DE [5UG1CA189819]
- Duke University - Duke Cancer Institute LAPS, Durham, NC [5U10CA180857]
- Florida Hospital Orlando, Orlando, FL
- Heartland Cancer Research NCORP, Decatur, IL [5UG1CA189830]
- MedStar Georgetown University Hospital, Washington, DC
- Ohio State University Comprehensive Cancer Center LAPS, Columbus, OH [5U10CA180850]
- Southeast Clinical Oncology Research (SCOR) Consortium NCORP, Winston-Salem, NC [5UG1CA189858]
- State University of New York Upstate Medical University, Syracuse, NY
- UNC Lineberger Comprehensive Cancer Center LAPS, Chapel Hill, NC [5U10CA180838]
- University of Chicago Comprehensive Cancer Center LAPS, Chicago, IL [5U10CA180836]
- University of Nebraska Medical Center, Omaha, NE
- University of Vermont College of Medicine, Burlington, VT
- VCU Massey Cancer Center Minority Underserved NCORP, Richmond, VA [UG1CA189869]
- Wake Forest University Health Sciences, Winston-Salem, NC
- Washington University - Siteman Cancer Center LAPS, Saint Louis, MO [U10CA180833]
- Weill Medical College of Cornell University, New York, NY
This multicenter, phase II trial tested the tolerability and efficacy of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma (FL). Patients with grade 1-3a FL, stage 3-4 or bulky stage 2, FL international prognostic index (FLIPI) 0-2, and no prior therapy were eligible to receive rituximab 375 mg/m(2) weekly during cycle 1 and day 1 of cycles 4, 6, 8, and 10, plus lenalidomide 20-25 mg on days 1-21 for twelve 28-day cycles. The primary objectives were to evaluate response rates [complete (CR) and overall] and time to progression. Secondary objectives included toxicity, response according to polymorphisms in FcgR2A and FcgR3A, and changes in circulating pro-angiogenic cells. From October 2010 to September 2011, 66 patients were enrolled. Median age was 53 years, 34 were female, 15 had bulky disease, 21 were FLIPI 0-1, 43 FLIPI 2, and 2 FLIPI 3. One patient withdrew before receiving treatment. Fifty-one patients completed 12 cycles of lenalidomide. Reasons for discontinuation included withdrawal (n = 6), adverse events (n = 6), progression (n = 2). Grade 3-4 hematologic toxicity included neutropenia (21%), lymphopenia (9%), and thrombocytopenia (2%), infection (11%), and rash (8%). Grade 1-2 toxicity included fatigue (78%), diarrhea (37%), rash (32%), and febrile neutropenia in one patient. The overall response rate was 95%; the CR rate was 72% (95% confidence interval, 60% to 83%). With a median follow-up of 5 years, the 2- and 5-year progression-free survival were 86% and 70%, respectively, and the 5-year overall survival was 100%. There was no association between CR rate or PFS and FLIPI, histological grade, bulky disease, FcgR2A/FcgR3A polymorphism, or change in circulating endothelial cell/hematopoietic progenitor cell. Lenalidomide plus rituximab was associated with low rates of grade 3-4 toxicity, yielded a CR rate and PFS similar to chemotherapy-based treatment and may represent a reasonable alternative to immunochemotherapy in previously untreated FL. NCT01145495.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据